SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter and be entered to win a Free iPod Touch visit http://www.smallcapreview.com/.
Clean Energy Fuels (Nasdaq: CLNE) $15.97. Today announced it has secured a new 10-year contract from the Los Angeles County Metropolitan Transit Authority (METRO) to upgrade, operate and maintain CNG bus fueling facilities supporting two METRO operating divisions.
Over the next 12 months, Clean Energy will reconfigure and upgrade CNG station compressor equipment at METRO stations that supply CNG bus fleets deployed in the agency’s Los Angeles Central and South Bay divisions. Between the two divisions, the CNG fuel requirement is expected to exceed nine million gallons per year.
METRO currently operates North America’s largest CNG-powered transit bus fleet. The agency’s more than 2,500 clean-burning CNG buses comprise 95% of its overall fleet. METRO secured grant funding for this CNG station upgrade project from the federal program created by the 2009 American Recovery and Reinvestment Act.
What They Do: Clean Energy is the leading provider of natural gas for transportation in North America.
Orexigen Therapeutics (Nasdaq: OREX) $4.15. Today announced results from a 24-week open-label study demonstrating that treatment with Contrave resulted in significant improvements in depressive symptoms that was accompanied by weight loss and improved control of eating in overweight and obese patients with major depression.
The primary endpoint of the study was the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) at 12 weeks on an intent-to-treat (ITT) basis. Treatment with Contrave32 (32mg naltrexone sustained release (SR)/360mg bupropion SR) resulted in the MADRS score decreasing from an average of 23.7 at baseline (consistent with moderate depression) to 10.5 (mild depression) (p<0.001) at week 12 and further decreasing to 8.4 (remission) at week 24 (p<0.001). Patients who completed the study lost an average of 9.2% of total body weight and reported substantial reductions in hunger, strength and frequency of food cravings and demonstrated improved control of eating.
What They Do: Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity.
Aeterna Zentaris (Nasdaq: AEZS) $1.21. Today announced a collaborative study with Almac's Diagnostics division for the Company's doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108, aimed at determining LHRH receptor expression through the development of a companion diagnostic tool. Selection for treatment with AEZS-108 is determined on the basis of LHRH receptor expression, currently measured immunohistochemically. In humans, LHRH receptors are expressed in ovarian, endometrial, breast, bladder, prostate and pancreatic tumors. AEZS-108 is currently in Phase 2 trials for advanced LHRH receptor positive ovarian and endometrial cancer.
Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, "We are very pleased with the collaboration with Almac who have proven experience in the development and validation of companion diagnostic tools and potential biomarkers in cancer indications. AEZS-108 is a promising anticancer compound, as demonstrated by the positive final Phase 2 results in ovarian cancer expressing LHRH receptors, recently disclosed at the last ASCO meeting. This state of the art companion diagnostic tool will allow us to develop improved methods of selecting the most appropriate patients to be treated with AEZS-108 in order to enhance the efficiency of our clinical trials and help us with the future successful development of AEZS-108 in a number of different LHRH expressing cancers."
What They Do: Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
